New combo therapy aims to tackle tough pancreatic tumors
NCT ID NCT02207465
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tests a combination of radiation therapy and the chemotherapy drug Abraxane (nab-paclitaxel) in people with pancreatic cancer that cannot be surgically removed. The goal is to find the safest and most effective doses to improve local tumor control and survival. The study involves 42 participants and will also explore adding another drug, paricalcitol, in some cases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abraxane (nab-paclitaxel) combined with radiation therapy
What this could lead to
If successful, this could lead to a more effective treatment option for people with pancreatic cancer that cannot be removed by surgery, potentially improving local tumor control and survival.
What could go wrong
This is an early phase 1 trial with only 42 participants, so results may not apply to everyone. The main goal is to find safe doses, not to prove effectiveness. Side effects from the combination of chemotherapy and radiation are expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Chester County Hospital
West Chester, Pennsylvania, 19380, United States